Statin and aspirin for chemoprevention of hepato- cellular carcinoma: Time to use or wait further?

Citations

WEB OF SCIENCE

28
Citations

SCOPUS

29

초록

Preclinical studies highlighted potential therapeutic applications of aspirin and statins as anticancer agents based on their pleiotropic effects. Epidemiologic studies suggested the role of aspirin and statins in the chemoprevention of hepatocellular carcinoma (HCC). However, observational data is prone to bias, and no prospective randomized trials are currently available to assess the risks and benefits of statin or aspirin therapy for chemoprevention of HCC. It is therefore important for clinicians and researchers to be aware of the quality of current evidence regarding this issue. In this review, we summarize currently available evidence to assist clinicians with their decision to use statin or aspirin and provide information for further clinical investigations. (Clin Mol Hepatol 2022;28:380-395)

키워드

Statins; Aspirin; Hepatocellular carcinoma; Chemoprevention; HEPATOCELLULAR-CARCINOMA; LIVER-CANCER; ANTIPLATELET THERAPY; ANTIVIRAL THERAPY; RISK; SIMVASTATIN; DEATH; ASSOCIATION; SURVIVAL; GROWTH
제목
Statin and aspirin for chemoprevention of hepato- cellular carcinoma: Time to use or wait further?
저자
Goh, Myung Ji; Sinn, Dong Hyun
DOI
10.3350/cmh.2021.0366
발행일
2022-07
유형
Review
저널명
Clinical and Molecular Hepatology
권
28
호
3
페이지
380 ~ 395